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ABSTRACT
Epstein-Barr virus is an unusual pathogen in the aetiology of 
alveolitis. We describe a case of Epstein-Barr virus induced 
pneumonitis and its successful treatment with Aciclovir.
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CASE REPORT
A 62-year-old female with a history of polymyositis was 
admitted with a four-week history of increasing dyspnoea. She 
had been treated with maintenance oral steroid therapy over 
the previous 4 years, augmented with oral cyclophosphamide 
over the preceding 4 weeks. On examination there were fine 
crepitations to the mid-zones. The patient was hypoxic with 
a Pa02 of 10.2 KPa on inspired FiO2 of 0.6. C reactive protein 
was  elevated  at  212  mg/L.  Echocardiogram  was  normal. 
Initial chest X-ray was normal (figure 1). A CT Pulmonary 
Angiogram  (CTPA)  was  then  performed  and  thrombus 
excluded, however inspiratory and expiratory high-resolution 
(HRCT) scans were obtained subsequent to the CTPA due to 
the grossly abnormal appearance of the lung parenchyma on 
lung windows. High resolution scan images demonstrated 
widespread  marked  ground  glass  opacity  with  intra  and 
interlobular  septal  thickening  in  keeping  with  a  diffuse 
alveolitis  (figure  2a  and  2b).  Ground  glass  opacification 
describes the findings on HRCT of the lungs in which there 
Fig 1: Normal chest radiograph on admission.
Fig 2a: Coronal reformat reproduced from CTPA study 
demonstrating wide spread ground glass opacity (white arrows).
Fig 2b: Transaxial HRCT image at level of the carina showing 
intralobular interstitial thickening (black arrow), interlobular septal 
thickening (grey arrow) and ground glass opacity (white arrow).© The Ulster Medical Society, 2009.
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is a hazy increased attenuation of lung with preservation 
of bronchial and vascular margins. This appearance can be 
caused by partial filling of air spaces, interstitial thickening, 
partial collapse of alveoli, normal expiration, or increased 
capillary  blood  volume1. The  presence  of  numerous  intra 
and interlobular septa almost always indicate the presence 
of an interstitial abnormality, only a few septa should be 
visible  in  normal  patients.  Septal  thickening  can  be  seen 
in  the  presence  of  interstitial  fluid,  cellular  infiltration  or 
fibrosis2. Diffuse alveolitis refers to the combination of these 
appearances throughout both lung fields suggestive of an 
acute inflammatory process of the pulmonary alveoli.
The patient subsequently required intubation and ventilation; 
EBV was identified on endotracheal aspirate with a copy 
number of 28,420/ml on quantitative PCR. No other bacterial, 
viral or fungal infection was identified. The patient was then 
treated with IV Aciclovir with subsequent dramatic clinical 
and  radiological  improvement  (figure  3).  EBV  was  not 
detectable on repeat airway aspirate following treatment.
This  patient  was  predisposed  to  infection  in  the  setting 
of  chronic  disease  and  ongoing  immunosuppression. The 
normal echocardiogram findings combined with the absence 
of features of cardiac failure make pulmonary oedema less 
likely as a contributing factor. This is also supported by the 
presence of an inflammatory response, which responded to 
antiviral treatment and associated radiological resolution.
EBV has been proposed in the pathogenesis of cryptogenic 
fibrosing alveolitis and more recently has been implicated in 
interstitial lung disease resembling sarcoidosis3. The role of 
EBV as an infective agent in the development of lung disease 
is controversial and there are few reports of symptomatic 
pulmonary involvement directly attributable to EBV infection. 
There is no single anti-viral agent specifically indicated in 
the treatment of pulmonary EBV infection. There have been 
case reports describing favourable outcomes with the use of 
Aciclovir4. This case supports the use of IV Aciclovir in EBV 
associated pneumonitis.
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Fig 3: Follow-up transaxial CT chest image demonstrating marked 
improvement in interstitial changes.